Novo Nordisk drug trial fails to protect heart
The experimental drug from Novo Nordisk, which was hoped to reduce the risk of heart attacks and strokes, failed in a large clinical trial involving more than 6,300 people. Despite lowering levels of the target protein, the study did not show a reduction in cardiac risk, and there was an increase in serious infections among participants compared to the placebo, leading to a stock decline of up to 10.5%, the largest loss in months. The company announced its intention to continue testing the drug to assess its impact on other heart conditions, with new results expected in the first half of next year.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)